This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Arsenakis, M Articles by May, J T Search for Related Content PubMed PubMed Citation Articles by Arsenakis, M Articles by May, J T

 Previous Article  |  Next Article 

Infect Immun. 1981 July; 33(1): 22-28

Complement-fixing antibody to the AG-4 antigen in herpes simplex virus type 2-infected patients.

ABSTRACT

Sera collected from confirmed herpes simplex virus type 2 (HSV-2) patients were found to be devoid of complement-fixing antibody to the AG-4 antigen at the time of the herpes lesion outbreak in 10 out of 13 cases. However, 1 to 4 weeks after HSV-2 lesion appearance, 28 out of 30 patients acquired complement-fixing antibody to the AG-4 antigen. The sera of these patients contained immunoglobulin M antibody activity and the ability to immunoprecipitate a 160,000-molecular weight early HSV-2 antigen (the AG-4 antigen). Also, these sera were used to show that a variety of anti-herpes virus compounds had a negligible effect on AG-4 production in HSV-2-infected HEp-2 cells. The majority of the compounds tested (including acycloguanosine and phosphonoformate) are known to inhibit late antigen production, suggesting that the AG-4 antigen is an early antigen. It is probably an immediate early antigen (alpha) as it is formed in the presence of cycloheximide and actinomycin D, a treatment which is used to accumulate alpha proteins.